Camber started the year off strongly with the addition of 9 new generic products in Q1 2026, putting the company on track to achieve its goal of 35+ product launches. These launches emphasize Camber’s continued investment in expanding patient access to high-quality, affordable treatments.
“Each product we launch represents another step toward expanding access for people who need it most,” said Scott Hettenhausen, Vice President of Rx Sales. “With every addition to our portfolio, we remain focused on delivering medications that can make a meaningful difference in patients’ lives.”
With capabilities extending beyond traditional tablets, capsules, and liquids to include specialty and injectable products, we can meet broader industry needs and support more diverse populations.
Tom DeStefano, VP Specialty Sales adds, “The expansion of the specialty portfolio allows us to broaden our reach, meet complex needs and reinforce our commitment to improving patient outcomes. Camber & the Specialty Division are working with health systems and other institutional customers to help mitigate drug shortages for high volume products, and those in oncology”.
As we look ahead, Camber anticipates 43 ANDA approvals and 40 ANDA filings for 2026. The following products were launched in Q1 2026:
